AI주식인사이트AI Stock Insight
C

큐리언트

115180KOSDAQ

46.0 / 100

Reference Date: 2026-10-23

Financial Score10.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure15.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Curient is a biotech company specializing in new drug development, established with government and international investments to advance Korea's pharmaceutical and biotech industry. Collaborating with institutions like the French Pasteur Institute and Germany's Max Planck Society, it focuses on infectious disease and oncology/immunology therapies. Partnering with MSD, it develops combination therapies with Keytruda, and reported consolidated sales of 92 billion KRW in 2024.

Number of Employees

32people

Average Salary

141.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
19.30Industry Average 1.200.0Point

16.1x industry avg (risky)

ROE
-68.05Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
48.23Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼11.2% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼13.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -57.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 20,150Won52-week high 50,90052-week low 14,850
1-month return1.0Point

1m -7.57% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

10 totalPositive 4Neutral 6Negative 0
  • Positive권리락 (유상증자)2026-10-16
  • Neutral투자설명서2026-10-16
  • Positive유상증자1차발행가액결정2026-10-16
  • Neutral[발행조건확정]증권신고서(지분증권)2026-10-16
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-10-16